Pre-made Ramucirumab benchmark antibody ( Whole mAb, anti-KDR therapeutic antibody, Anti-FLK1/CD309/VEGFR/VEGFR2 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-468

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-468 Category Tag

Product Details

Pre-Made Ramucirumab biosimilar, Whole mAb, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ramucirumab (LY3009806, IMC-1121B, trade name Cyramza) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.

Products Name (INN Index)

Pre-Made Ramucirumab biosimilar, Whole mAb, Anti-KDR Antibody: Anti-FLK1/CD309/VEGFR/VEGFR2 therapeutic antibody

INN Name

Ramucirumab

Target

KDR

Format

Whole mAb

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Approved

Est. Status

Active

100% SI Structure

3s34:HL/3s37:HL/3s36:HL

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2008

Companies

Dyax,AstraZeneca,Dana-Farber Cancer Institute,Eli Lilly,Merck Sharp & Dohme,University of Texas M. D. Anderson Cancer Center,Washington University School of Medicine

Conditions Approved

Colorectal cancer,Gastric cancer,Non-small cell lung cancer,Liver cancer

Conditions Active

Oesophageal cancer,Urogenital cancer,Biliary cancer,Carcinoid tumour,Solid tumours,Pancreatic cancer

Conditions Discontinued

Breast cancer,Malignant melanoma,Ovarian cancer,Prostate cancer,Renal cell carcinoma

Development Tech

Dyax Human Phage Display

Previous Name

NA

Gm Offical Target Name

KDR

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide